.png){kind=logo}
US-based sterile injectable (pre-filled syringe) manufacturing facility focused on small-molecule generic 505b2 and 505j products.
Minimally-invasive nitinol implant delivered into prostatic urethra and indicated to re-open the prostatic urethra in BPH patients, restoring urinary flow.
HOW WE USE YOUR INFORMATION
-
to operate, manage, develop and promote our business and, in particular, our relationship with you and the organization you represent (if any) and related investments and/or transactions;
-
to operate, administer and improve our website and premises and other aspects of the way in which we conduct our operations;
-
to protect our business from fraud, money-laundering, breach of confidence, theft of proprietary materials and other financial or business crimes;
-
to send marketing communications to you, if applicable and
-
to comply with our legal and regulatory obligations and bring and defend legal claims.
We may review information about you that we maintain in our systems, including the contents of and information related to your emails and other communications with us, for compliance and business-protection purposes as described above. This may include reviews to disclose information relevant to litigation and/or reviews of records relevant to internal or external regulatory or criminal investigations. To the extent permitted by applicable law, these reviews will be conducted in a reasonable and proportionate way and approved at an appropriate level of management. They may ultimately involve the disclosure of your information to governmental agencies and litigation counterparties as described below. Your emails and other communications may occasionally be accessed by persons other than the staff member with whom they are exchanged for ordinary business management purposes (for example, where necessary when a staff member is out of the office or has left New Rhein).
We will only use your personal information for the purposes for which we collected it, unless we reasonably consider that we need to use it for another reason and that reason is compatible with the original purpose. If you wish to get an explanation as to how the processing for the new purpose is compatible with the original purpose, please contact us.
If we need to use your personal information for an unrelated purpose, we will notify you and we will explain the legal basis which allows us to do so.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
SHANKAR HARIHARAN, PHD
Dr. Hariharan is the Executive Vice President and Chief Scientific Officer at Amneal Pharmaceuticals, Inc. At Amneal, Dr. Hariharan oversees Research & Development, Regulatory Affairs, and Specialty Pharmaceutical Dosage Development. Dr. Hariharan has over 30 years of experience in successfully leading branded and generic pharmaceutical businesses and has held leadership positions at companies including International Development Research, Forest Labs, and Par Pharmaceuticals. Prior to joining Amneal, Dr. Hariharan founded DermAct, an R&D organization specializing in dermatology. Dr. Hariharan completed his bachelor’s degree in pharmacy at Banaras Hindu University in India and his doctorate in pharmacy at Northeastern University in Boston, Massachusetts.
_edited.jpg)
Roland Turck, MD
Executive in Residence
Dr. Roland Turck is an international Biotech-Pharma Executive and Medical Doctor experienced in both Big Pharma and Biotech. He has founded the consulting firm TurckBio that supports executive teams, boards, and investors of biotech companies. TurckBio provides advice on strategy, clinical development, and commercialization in the specialty medicine field. Roland has a proven P&L track record and the ability to translate science into commercial success, he has built businesses, expanded franchises, launched brands, and has driven commercial performance at the global, regional, and country-level in both mature and emerging market. He has driven profitable growth of portfolios ranging from 20 MM US$ to 4,000 MM US$. Roland is considered an expert in Specialty Medicine and has extensive first-hand experience and a deep understanding of clinical development, strategy, and commercialization in Oncology, Neurology, Orphan Drugs, Radiopharmaceuticals, Diagnostic and Molecular Imaging. Prior to TurckBio, Roland co-founded an Immuno-oncology company (recently sold). In his corporate career, Roland was President of Bayer’s Global Specialty Medicine business, where he increased portfolio value by 40%. He orchestrated the launch of major brands such as Xofigo, Eylea, and Stivarga, transformed Oncology into a rapidly growing sustainable franchise, unlocking the value of the underperforming Diagnostic Imaging business, entered Ophthalmology, and turned the Hemophilia business around. In his prior operational role as Region Head for Latin America, he successfully led the integration of Bayer and Schering, achieved faster than market growth while driving profitability, and expanded portfolio through deals. Roland is a strategic mind firmly grounded in reality owing to his extensive operative experience. He gained hands-on experience in various country organizations, he gained strategic experience as a member of the Bayer Pharma Global Executive Committee and in his other senior executive roles. Throughout his career, Roland has led organizations through various challenges such as acquisitions, integration, rapid growth periods, scaling-up, restructuring, turnaround, downsizing, and these experiences have made him very versatile. Roland is truly a global player who understands both mature and emerging markets. He experienced the value of diversity working and living on all continents.